Free Newsletter
Tougher FDA bars seven researchers from new studies
So far this year a more vigilant FDA has barred seven physicians from conducting medical research work. The actions equal the number of actions taken by the agency over the past three years.
The FDA has come under increasing pressure to take action against researchers accused of fraud. Critics have maintained that the agency often takes years before moving to bar a researcher from new studies. And one of the seven barred in the first half of this year was Maria Anne Kirkman Campbell, a researcher who admitted five years ago to research fraud in a Sanofi-Aventis study. An FDA spokesperson says the agency has adopted a new, tougher time line on such actions and is in the process of hiring new staffers to beef up enforcement.
- read the report in Pharmalot
Related Articles:
Are researchers facing FDA crackdown on trial fraud?
Report: FDA lax in clinical trial oversight
FDA reviews new rules for clinical trials
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: